494
Participants
Start Date
December 9, 2024
Primary Completion Date
September 30, 2025
Study Completion Date
March 16, 2026
Petrelintide
Petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
Placebo
Matching placebo to petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
CHEAR Center LLC, The Bronx
Altoona Center for Clinical Research - Research, Duncansville
Manaasas Clinical Research Center, Manassas
PharmQuest Life Sciences, LLC, Greensboro
Javara Inc, Charlotte
Lucas Research, Inc., New Bern
Century Research LLC, Miami
Palm Beach Research Center, West Palm Beach
Excel Medical Clinical Trials, LLC, Boca Raton
Innovative Research of West Florida, Inc., Clearwater
University of Alabama at Birmingham, Birmingham
Alliance for Multispecialty Research, Knoxville
Alliance For Multispecialty Research, LLC, Lexington
Mercury Street Medical Group, PLLC, Butte
Great Lakes Clinical Trials LLC dba Flourish Research, Chicago
AMR Wichita East, Wichita
AMR Norman, Norman
Clinical Trials of Texas, LLC., dba Flourish Research, San Antonio
Top Diabet, Craiova
Spitalul Clinic Judetean de Urgenta Sf Apostol Andrei Constanta, Constanța
Clinical Research Center of Florida, Pompano Beach
Krakowskie Centrum MedyczneSp.z o.o, Krakow
ETG Siedlce, Siedlce
FutureMeds Warszawa Centrum, Warsaw
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych i Administracji, Warsaw
ETG Warszawa, Warsaw
FutureMeds Targowek, Warsaw
Futuremeds Olsztyn, Olsztyn
Institutul National de Endocrinologie C I Parhon, Bucharest
Institutul Clinic Fundeni, Bucharest
Fundatia Dr Victor Babes, Bucharest
Institutul De Pneumoftiziologie Marius Nasta, Bucharest
Lead Sponsor
Collaborators (1)
Parexel
INDUSTRY
Zealand Pharma
INDUSTRY